ICICI Securities Limited is the author and distributor of this report

03 June 2024

India | Equity Research | Company Update

Syrma SGS Technology

White Goods

Strong revenue growth momentum to continue

We hosted Syrma's management in Mumbai to meet with institutional investors. We remain enthused about Syrma's growth prospects. Takeaways: (1) Strong revenue growth run-rate is expected to continue in FY25/FY26 due to demand tailwinds. Syrma is likely to maintain 40%-plus revenue growth YoY in FY25/FY26. (2) Higher contribution of volume-based consumer business (largely telecom business with lower margins) has led to overall margins declining. However, margins shall stabilise at 7% in FY25 [6.3% in FY24 (6.8% in forex)]. (3) Syrma's production capacity has almost doubled in FY24 (6.1mn components p.a. as of FY24, from 3.2mn in FY23) and is likely to further expand by FY25-end. (4) Exports are likely to continue its growth momentum in FY25 with revenues scaling past INR 10bn. (5) Syrma is scouting for inorganic acquisition opportunities in the aerospace/defence segments.

We believe Syrma is likely to continue its strong revenue growth momentum over the next two years led by a strong order book and capacity expansion. While margins have declined due to product mix change, it may revive, following growth in its margin-accretive exports segment, operating leverage and PLI benefits. Maintain **BUY**.

7% margin likely for FY25, in our view

Syrma's EBITDA margin contracted over past FY21–24 (11.3% in FY21 to 6.3% in FY24). Change in revenues mix has primarily weighed on the margins. Higher revenue share of volume-based consumer business has resulted in margin decline. However, the margin may stabilise to 7% in FY25 led by: (1) higher exports (margin accretive); and (2) operating leverage. We believe there is upside risks to 7% with likely PLI benefits.

2x capacity expansion in FY24

Syrma has almost doubled its production capacity in FY24 (6.1mn components p.a., as of FY24, from the earlier 3.2mn components p.a.). The capacity utilisation levels have declined to \sim 65% in FY24, from 75–80% in FY23 due to gradual ramp-up in new production capacities. We note, the profitability was impacted in FY24 due to: (1) higher overhead costs; (2) lower utilisation level; and (3) higher depreciation.

Aniruddha Ioshi

aniruddha.joshi@icicisecurities.com +91 22 6807 7249

Karan Bhuwania

karan.bhuwania@icicisecurities.com

Nilesh Patil

nilesh.patil@icicisecurities.com

Market Data

85bn
1,022mn
SYRMA IN
SYRM.BO
705/381
33.0
4.7

Price Performance (%)	3m	6m	12m
Absolute	(8.4)	(15.1)	22.3
Relative to Sensex	(10.5)	(25.5)	4.2

Financial Summary

Y/E March (INR mn)	FY23A	FY24A	FY25E	FY26E
Net Revenue	20,484	31,538	46,135	62,515
EBITDA	1,878	1,985	3,456	4,676
EBITDA Margin (%)	9.2	6.3	7.5	7.5
Net Profit	1,193	1,087	1,893	2,764
EPS (INR)	6.8	6.1	10.7	15.6
EPS % Chg YoY	21.5	(9.3)	74.2	46.0
P/E (x)	71.1	78.4	45.0	30.8
EV/EBITDA (x)	42.5	44.0	25.2	19.0
RoCE (%)	7.9	5.2	8.4	10.8
RoE (%)	11.2	6.7	10.8	14.1

Previous Reports

13-05-2024: <u>Q4FY24 results review</u> 08-02-2024: <u>Q3FY24 results review</u>



Automotive segment likely to grow on strong EV traction

Automotive segment has reported strong 61.2% YoY growth in FY24 (3-year CAGR: 70.7%). Strong client addition and higher use of electronics in EVs have primarily led to strong growth over the past three years. In our view, Syrma may continue the strong growth trajectory in its automotive business, following high traction for EV components. In addition to its anchor customer TVS Motors, the company has added eight—nine clients in the two-wheeler segment.

Strong momentum in exports to continue

Exports segment has registered 32.4% YoY growth in FY24. It contributes ~26% to total sales. Syrma has crossed the INR 8bn milestone in exports (3-year revenue CAGR: 19.4%). Industrial and healthcare segments contribute majorly to Syrma's exports segment.

The company has a strong order book for its exports segment, which offers revenue visibility. Traction in the exports segment is likely to continue in FY25 and exports are likely to scale past INR 10bn (INR 8bn ex-Johari). Growth in the margin-accretive export business will aid Syrma in improving its overall margin.

Scope for inorganic acquisitions

Syrma's Johari Digital Healthcare Limited (JDHL) acquisition in Sep'23 had further strengthened its offerings in healthcare segment. At present, Syrma has limited/low presence in aerospace and defence. We believe the company may acquire companies (relatively similar in size to JDHL) catering to these end-user industries.

We believe, such acquisitions will not only help Syrma have a strong presence across all major sectors in the EMS space, but also boost its margin profile (aerospace and defence segments yield relatively higher margins).

Maintain BUY

We model Syrma to report revenue/PAT CAGR of 40.8%/59.5% YoY over FY24–26E. Retain **BUY** with a DCF-based revised TP of INR 600 (implied P/E of 38x FY26E).

Key risks: Higher commodity prices; and increase in competitive pressures.




Strong revenue growth momentum to continue

Revival in EBITDA margin likely in FY25, in our view

We note Syrma's EBITDA margin band has deteriorated from 11–11.5% between FY19-21 to 9–10% in the FY22–23 period and further to <6.5% in FY24. Higher contribution to total sales from margin accretive industrial and healthcare segment (60-62%) has likely resulted in superior margins during FY19-FY22. However, we note, the contribution from its volume-based businesses such as automotive and consumer has significantly improved over the past two years (~40% in FY22 to 60%-plus in FY24). It has primarily led to a deterioration in its margin trajectory.

We believe margins may expand from its lows of 6.3% in FY24 to 7%-plus in FY25E led by: (1) strong growth traction in margin accretive exports business; and (2) operating leverage.

Exhibit 1: EBITDA margin trajectory to improve from low of FY24



Source: Company data, I-Sec research

Consumer segment's higher revenue contribution, drag on profitability

Syrma's consumer segment largely comprises of its telecom and electronics businesses, at present. Telecom business comprises of fibre-to-home consumer-oriented products that generates lower gross margin (<10%). Higher contribution of consumer segment (largely due to telecom business) has resulted in lower profitability in FY24. We believe the contribution from consumer business may reduce to \sim 37% in FY25, from its current 40%-plus levels. We reckon margin/profitability may improve led by: (1) lower contribution from the consumer business to total sales; and (2) operating leverage.

Exhibit 2: Contribution of consumer business grew 2x over FY22-FY24

Revenue as % of Total Sales	FY19	FY20	FY21	FY22	FY23	FY24
Consumer	20.5%	22.6%	23.4%	20.3%	32.2%	40.0%
Other businesses	79.5%	77.4%	76.6%	79.7%	67.8%	60.0%
Total	100%	100%	100%	100%	100%	100%


Source: Company data, I-Sec research



Strong capacity ramp-up to cater high demand

Syrma has expanded its production capacity from 3.2mn components earlier to 6.1mn p.a. in FY24. Capacity utilisation stood at 65% in FY24. With expanded capacity and higher utilisation levels, the company has the potential to generate revenues of INR 45bn in FY25E. The company is witnessing strong demand for all its operating segments, and thus, will likely continue its strong revenue growth run-rate in FY25E.

Exhibit 3: Production capacity has grown ~2x YoY



Source: Company data, I-Sec research

Electric vehicles (EV) boosting automotive segment

Syrma's automotive segment has consistently posted 50%-plus revenue CAGR in FY21–24. Marquee client additions, new product launches and strong traction in its EV segment have largely boosted growth for its automotive segment. The automotive business generates 19–22% gross material margins. The emergence of EVs (particularly in two-wheeler segment) is driving incremental growth for the segment. Syrma has added eight–nine clients in the two-wheeler segment in addition to its anchor customer i.e., TVS Motors. Segmental sales may scale to INR 8.5–10bn in FY25, from INR6.5bn in FY24.

Exhibit 4: Strong growth in automotive segment YoY

Particular	FY21	FY22	FY23	FY24
Automotive (INR mn)	1306.3	2514.9	4029.0	6495.0
Growth YoY (%)	-	92.5%	60.2%	61.2%

Source: Company data, I-Sec research



Growth in exports – a key driver for margin expansion

Syrma's exports revenue scaled past the INR 8bn mark in FY24 (3-year CAGR: 19.4%). The company's exports primarily comprise of industrial and healthcare orders. Contribution from automotive and consumer is relatively lower. Thus, high growth in the exports segment will likely lead to margin expansion for the company (industrial and healthcare are high margin businesses compared to automotive and consumer). We believe strong growth in its export business may continue in FY25 (likely to scale to INR 10bn-plus in FY25).

Exhibit 5: Strong growth in exports business YoY


Particular	FY21	FY22	FY23	FY24	CAGR (%)
Exports (INR mn)	4823.0	5525.5	6195.6	8199.9	19.4%
Growth YoY (%)	-	14.6%	12.1%	32.4%	-

Source: Company data, I-Sec research

Likely expansion of aerospace/defence business via acquisition

Syrma acquired Johari Digital Healthcare Limited (JDHL) in Sep'23 to strengthen its healthcare business. We believe, Syrma is likely to continue a similar trend to strengthen its aerospace/defence business, which is relatively smaller in size at present. Aerospace/defence is a high margin business. We reckon Syrma may aim to acquire a similar JDHL-sized company for acquisition.

Exhibit 6: Syrma's segment-wise growth strategy




Source: Company data, I-Sec research




Key charts - Annual

Exhibit 1: Revenue and growth rates




Source: Company data, I-Sec research

Exhibit 2: EBITDA margin




Source: Company data, I-Sec research

Exhibit 3: Net profit and growth rates




Source: Company data, I-Sec research

Exhibit 4: RoE and RoCE




Source: Company data, I-Sec research

Exhibit 5: Net working capital days



Source: Company data, I-Sec research

Exhibit 6: OCF/EBITDA



Source: Company data, I-Sec research



Valuation and risks


We model Syrma SGS to report revenue/PAT CAGRs of 40.8%/59.5% over FY24–26E while RoE may move up to 13.8% in FY26E, from 6.7% in FY24. At our DCF-based TP of INR 600, implied P/E works out to 38x FY26E EPS. Maintain **BUY**.

Exhibit 7: DCF-based valuation

Particulars	
Cost of Equity (%)	11.6%
Terminal growth rate (%)	4.0%
Discounted interim cash flows (INR mn)	34,218
Discounted terminal value (INR mn)	72,239
Total equity value (INR mn)	1,06,456
Value per share (INR)	600

Source: Company data, I-Sec research

Exhibit 8: Mean PE (x) and standard deviations



Source: I-Sec research, Bloomberg

Risks

Sharp increase in input prices and competitive pressures

Major increase in input prices and/or increase in competitive pressures may result in downside to our estimates.

Delays in launch of new plants/products

Any delays in launch of new products and/or plants may result in lower earnings than estimated.

Exhibit 9: Shareholding pattern

%	Sep'23	Dec'23	Mar'24
Promoters	47.2	46.9	46.9
Institutional investors	19.8	19.3	18.7
MFs and other	6.0	5.2	4.0
Fls/ Banks	0.0	0.0	0.0
Insurance Cos.	0.7	0.4	0.4
FIIs	13.1	13.7	14.3
Others	33.0	33.8	34.4

Source: Bloomberg, I-Sec research

Exhibit 10: Price chart



Source: Bloomberg, I-Sec research



Financial Summary

Exhibit 11: Profit & Loss

(INR mn, year ending March)

	FY23A	FY24A	FY25E	FY26E
Net Sales	20,484	31,538	46,135	62,515
Operating Expenses	18,606	29,553	42,679	57,839
EBITDA	1,878	1,985	3,456	4,676
EBITDA Margin (%)	9.2	6.3	7.5	7.5
Depreciation & Amortization	312	515	716	858
EBIT	1,566	1,470	2,740	3,818
Interest expenditure	216	378	529	463
Other Non-operating Income	437	586	331	354
Recurring PBT	1,787	1,678	2,541	3,709
Profit / (Loss) from Associates	-	-	-	-
Less: Taxes	556	421	648	946
PAT	1,231	1,257	1,893	2,764
Less: Minority Interest	38	170	-	-
Extraordinaries (Net)	16	(25)	-	-
Net Income (Reported)	1,210	1,062	1,893	2,764
Net Income (Adjusted)	1,193	1,087	1,893	2,764

Source Company data, I-Sec research

Exhibit 12: Balance sheet

(INR mn, year ending March)

	FY23A	FY24A	FY25E	FY26E
Total Current Assets	11,484	22,407	24,184	31,664
of which cash & cash eqv.	544	856	1,117	406
Total Current Liabilities & Provisions	5,969	13,330	14,533	19,692
Net Current Assets	5,515	9,077	9,652	11,972
Investments	8,351	3,552	3,552	2,552
Net Fixed Assets	4,142	7,533	8,736	9,878
ROU Assets	-	-	-	-
Capital Work-in-Progress	253	168	-	-
Total Intangible Assets	1,182	3,221	3,221	3,221
Other assets	-	-	-	-
Deferred Tax assets	-	-	-	-
Total Assets	19,443	23,552	25,161	27,623
Liabilities				
Borrowings	3,876	6,618	6,618	6,618
Deferred Tax Liability	138	164	164	164
provisions	-	-	-	-
other Liabilities	-	-	-	-
Equity Share Capital	1,768	1,774	1,774	1,774
Reserves & Surplus	13,635	14,352	15,961	18,423
Total Net Worth	15,403	16,126	17,735	20,197
Minority Interest	26	644	644	644
Total Liabilities	19,443	23,552	25,161	27,623

Source Company data, I-Sec research

Exhibit 13: Quarterly trend

(INR mn, year ending March)

	Jun-23	Sep-23	Dec-23	Mar-24
Net Sales	6,013	7,117	7,067	11,341
% growth (YoY)	54.4	52.4	37.9	66.9
EBITDA	369	490	388	737
Margin %	6.1	6.9	5.5	6.5
Other Income	221	89	121	156
Extraordinaries	(13)	(12)	1	(0)
Adjusted Net Profit	283	319	203	452

Source Company data, I-Sec research

Exhibit 14: Cashflow statement

(INR mn, year ending March)

	FY23A	FY24A	FY25E	FY26E
Operating Cashflow	(973)	(1,183)	2,295	591
Working Capital Changes	(2,299)	(2,804)	(314)	(3,030)
Capital Commitments	(1,184)	(3,377)	(1,750)	(2,000)
Free Cashflow	(2,157)	(4,560)	545	(1,409)
Other investing cashflow	(7,961)	2,734	-	1,000
Cashflow from Investing Activities	(9,145)	(643)	(1,750)	(1,000)
Issue of Share Capital	8,760	(80)	-	-
Interest Cost	-	-	-	-
Inc (Dec) in Borrowings	1,478	2,218	-	-
Dividend paid	-	(265)	(284)	(302)
Others	-	-	-	-
Cash flow from Financing Activities	10,238	1,873	(284)	(302)
Chg. in Cash & Bank balance	120	47	261	(711)
Closing cash & balance	465	520	1,117	406

Source Company data, I-Sec research

Exhibit 15: Key ratios

(Year ending March)

	FY23A	FY24A	FY25E	FY26E
Per Share Data (INR)				
Reported EPS	6.8	6.1	10.7	15.6
Adjusted EPS (Diluted)	6.8	6.1	10.7	15.6
Cash EPS	8.5	9.0	14.7	20.4
Dividend per share (DPS)	-	1.5	1.6	1.7
Book Value per share (BV)	87.1	90.9	100.0	113.8
Dividend Payout (%)	-	24.4	15.0	10.9
Growth (%)				
Net Sales	61.7	54.0	46.3	35.5
EBITDA	49.0	5.7	74.1	35.3
EPS (INR)	21.5	(9.3)	74.2	46.0
Valuation Ratios (x)				
P/E	71.1	78.4	45.0	30.8
P/CEPS	56.4	53.2	32.6	23.5
P/BV	5.5	5.3	4.8	4.2
EV / EBITDA	42.5	44.0	25.2	19.0
P / Sales	4.1	2.7	1.8	1.4
Dividend Yield (%)	-	0.3	0.3	0.4
Operating Ratios				
Gross Profit Margins (%)	24.8	20.5	22.0	22.0
EBITDA Margins (%)	9.2	6.3	7.5	7.5
Effective Tax Rate (%)	31.1	25.1	25.5	25.5
Net Profit Margins (%)	6.0	4.0	4.1	4.4
NWC / Total Assets (%)	25.6	34.9	33.9	41.9
Net Debt / Equity (x)	(0.3)	0.1	0.1	0.2
Net Debt / EBITDA (x)	(2.7)	1.1	0.6	8.0
Profitability Ratios				
RoCE (%)	7.9	5.2	8.4	10.8
RoE (%)	11.2	6.7	10.8	14.1
RoIC (%)	12.4	7.5	10.4	12.7
Fixed Asset Turnover (x)	5.1	4.5	4.7	5.3
Inventory Turnover Days	129	141	117	113
Receivables Days	89	131	80	78
Payables Days	131	186	132	128
Source Company data. I-Sec resec	arch			

Source Company data, I-Sec research



This report may be distributed in Singapore by ICICI Securities, Inc. (Singapore branch). Any recipients of this report in Singapore should contact ICICI Securities, Inc. (Singapore branch) in respect of any matters arising from, or in connection with, this report. The contact details of ICICI Securities, Inc. (Singapore branch) are as follows: Address: 10 Collyer Quay, #40-92 Ocean Financial Tower, Singapore - 049315, Tel: +65 6232 2451 and email: navneet_babbar@icicisecuritiesinc.com, Rishi garawal@icicisecuritiesinc.com.

"In case of eligible investors based in Japan, charges for brokerage services on execution of transactions do not in substance constitute charge for research reports and no charges are levied for providing research reports to such investors."

New I-Sec investment ratings (all ratings based on absolute return; All ratings and target price refers to 12-month performance horizon, unless mentioned otherwise) BUY: >15% return; ADD: 5% to 15% return; HOLD: Negative 5% to Positive 5% return; REDUCE: Negative 5% to Negative 15% return; SELL: < negative 15% return

ANALYST CERTIFICATION

I/We, Aniruddha Joshi, CA; Karan Bhuwania, MBA; Nilesh Patil, MBA; authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of the ICICI Securities Inc. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. Registered Office Address: ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025. CIN: L67120MH1995PLC086241, Tel: (91 22) 6807 7100. ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager, Research Analyst and Alternative Investment Fund. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number - INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities AIF Trust's SEBI Registration number is IN/AIF3/23-24/1292 ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Institutional Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Retail Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances. This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been managed by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/ beneficial ownership of one percent or more or other material conflict of interest in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

This report has not been prepared by ICICI Securities, Inc. However, ICICI Securities, Inc. has reviewed the report and, in so far as it includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.



Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk free return to the investors.

Name of the Compliance officer (Research Analyst): Mr. Atul Agrawal, Contact number: 022-40701000, E-mail Address: complianceofficer@icicisecurities.com

For any queries or grievances: Mr. Prabodh Avadhoot Email address: headservicequality@icicidirect.com Contact Number: 18601231122